[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"ibs-irritable-bowel-syndrome\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:ibs-irritable-bowel-syndrome":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,10,0,[8,47,76,105,132,157,183,209,235,261],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100641374","study-evaluating-the-effect-of-ucb8600-on-mast-cell-activation-in-the-human-gut-100641374",false,"NCT07655375","Study Evaluating the Effect of UCB8600 on Mast Cell Activation in the Human Gut","MASTGUT","Inclusion Criteria group 1 (resection tissue from surgery patients = healthy volunteers):\n\n1. Voluntary written informed consent of the participant has been obtained prior to any screening procedures\n2. At least 18 years of age at the time of signing the Informed Consent Form (ICF)\n3. Undergoing surgery for colorectal cancer\n4. No preoperative radiotherapy or chemotherapy\n\nExclusion Criteria group 1 (resection tissue from surgery patients = healthy volunteers):\n\n1. Using antihistamines such as ebastine, cetirizine, desloratadine, … (non-exhautive list) at the moment of surgery\n2. Inflammatory bowel disease (IBD) or diverticulitis\n3. Diabetes or BMI ≥ 30 kg\u002Fm²\n4. Subject is legally incapacitated\n\nInclusion Criteria group 2 (rectal biopsies from IBS patients):\n\n1. Voluntary written informed consent of the subject has been obtained prior to any screening procedures\n2. At least 18 years of age and maximum age of 65 years of age at the time of signing the Informed Consent Form (ICF)\n3. Diagnosed with IBS\n\nExclusion Criteria group 2 (rectal biopsies from IBS patients):\n\n1. Subject has internal\u002Fexternal hemorrhoids at the moment of biopsy sampling.\n2. Using bloodthinners such as Acenocoumarol, Aspirine (acetylsalicylzuur), Apixaban (Eliquis), Clopidogrel (Plavix), Dabigatran (Pradaxa), Edoxaban (Lixiana), Rivaroxaban (Xarelto), warfarine (Marevan®) and Enoxaparine (Clexane), … (non-exhausative list).\n3. Using antihistamines such as ebastine, cetirizine, desloratadine, … (non-exhausative list) at the moment of biopsy sampling. These should be stopped 2 weeks prior to the biopsy sampling.\n4. Subject is legally incapacitated",true,"ALL","18 Years","65 Years",{"count":21,"type":22},60,"ESTIMATED","INTERVENTIONAL",[25],"NA","Study evaluating the effect of UCB8600 on mast cell activation in the human gut:\n\nIBS is a disease characterized by abdominal pain and a change in stool. Treatment is limited to an adapted life style, dietary changes and medication to lessen cramps (spasmolytica), all of which have seen limited to no clinical success.\n\nRecently, we were able to demonstrate that mast cells play an active role in IBS symptoms. More specifically, they set histamine free when activated which heightens nerve sensitivity in the intestines which probably contributes to the abdominal pain. A new product called \"UCB8600\" is hypothesized to be able to counteract this by causing less mast cells to be activated. In this study we'll test this by administering UCB8600 on intestinal tissue and see if there is less mast cell activation. If the study produces good results, this new product could potentially be used as a treatment for IBS in the future.",[28],"IBS (Irritable Bowel Syndrome)",[30,31,32,33],"IBS","irritable bowel syndrome","UCB8600","mast cells","NOT_YET_RECRUITING","2026-06-18",{"date":37,"type":38},"2026-06-22","ACTUAL",{"date":40,"type":22},"2026-06",{"date":42,"type":22},"2028-04",{"name":44,"class":45},"Guy Boeckxstaens","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":23,"phases":55,"briefSummary":56,"conditions":57,"keywords":61,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":46},"100640341","a-study-evaluating-the-impact-of-regular-fodmap-targeting-digestive-enzyme-blend-use-on-gastrointestinal-symptoms-in-individuals-with-self-reported-bloating-100640341","NCT07591584","A Study Evaluating the Impact of Regular FODMAP-targeting Digestive Enzyme Blend Use on Gastrointestinal Symptoms in Individuals With Self-Reported Bloating","Inclusion Criteria:\n\n* Individuals aged 18 years old or older\n* Screening score of \\>= 55 on the PROMIS Scale v1.1 - Gastrointestinal Gas and Bloating 13a scale.\n* Screening severity score of \\>= 55 on the PROMIS Scale v1.0 - Gastrointestinal Belly Pain scale.\n* Screening score of \\\u003C10 on the Generalized Anxiety Disorder 7-item (GAD-7) scale\n* Adults with or without IBS are eligible; participants with IBS experiencing symptoms must meet the Rome IV criteria as determined by the Rome IV Diagnostic Questionnaire (R4DQ) IBS Module.\n* Able to maintain 80% compliance with daily questionnaires during the 2 week run-in period.\n* In good general health at the time of screening (Investigator discretion).\n* Able to read and understand English and provide informed consent.\n* Able to use a personal smartphone device and download Chloe by People Science.\n* Able to receive shipment of the product at an address within the United States.\n* Able to complete study assessments over the course of up to 19 weeks.\n\nExclusion Criteria:\n\n* Do not have a personal smartphone, internet access, or unwilling to download Chloe.\n* Concomitant Therapies:\n\nParticipants receiving any of the following treatments or therapies are excluded:\n\n* Any investigational therapies or treatments (pharmaceuticals, devices, supplements) within 30 days prior to randomization.\n* Ongoing psychological therapies specifically targeting gastrointestinal symptoms or functional disorders, including but not limited to GI-directed Cognitive Behavioral Therapy (CBT), GI hypnotherapy, or other therapies for Disorders of Gut-Brain Interaction (DGBI).\n* Treatment with Glucagon-like peptide-1 (GLP-1) agonists (e.g., semaglutide, tirzepatide) within the last 90 days prior to randomization, due to their known effects on gut motility and GI symptoms.\n* Current or recent (within the last 6 months) chemotherapy or immunotherapy for cancer treatment.\n* Current or planned use of any other digestive enzymes prescription or over-the-counter (OTC).\n* Chronic use (defined as daily use for \\>30 days within the last 90 days) of any medication known to have substantial gastrointestinal side effects (e.g., diarrhea, constipation, nausea) that, in the opinion of the Principal Investigator, may confound the assessment of study outcomes. This may include high-dose NSAIDs, opioids, prokinetics, bile acid binders, or certain antibiotics.\n* Variable use of probiotics, fiber supplements, laxatives, stool softeners, antidiarrheals (if taking) in the last 30 days. Variable use is defined as use of any probiotic, fiber supplement, laxative, stool softener, or antidiarrheal with a dose change greater than 50% in the last 30 days or initiation or discontinuation of a gut-active product in the last 30 days.\n\n  * Other Illnesses or Conditions:\n\nParticipants who have the following comorbidities or gastrointestinal illnesses are excluded:\n\n* Currently diagnosed with Alcohol Use Disorder and\u002For Substance Use Disorder\n* Currently pregnant, planning to become pregnant in the next 4 months, or breastfeeding\n* History of bariatric or other significant gastrointestinal surgery (e.g., small bowel resection, total colectomy) that has permanently altered GI anatomy or function. Standard appendectomy or cholecystectomy are generally permitted.\n\nAny underlying medical conditions or comorbidities that may confound the assessment of digestive symptoms or the evaluation of the study outcomes (e.g., Type I diabetes, Endometriosis, etc.).\n\n* Acute gastroenteritis within the past 4 weeks;\n* New diagnosis workup planned during study that may change diagnosis\u002F behavior\u002F medications (eg. colonoscopy prep or major bowel cleanse, upcoming GI consult that could affect eligibility).\n* Have a significant illness, disease or condition which, in the opinion of the principal investigator, may impact their ability to participate in the study or impact the study outcomes.\n\n  * Self-reported known hypersensitivity or previous allergic reaction to corn and\u002For any previous reaction to digestive enzyme supplements (eg. Beano and Lactaid)\n  * Comorbid GI conditions: IBD - Ulcerative Colitis or Crohn's Disease, Microscopic Colitis, history of small bowel or colonic surgeries, Celiac disease, or Bile Acid Malabsorption (BAM).\n  * Screening score of ≥10 on the Generalized Anxiety Disorder 7-item (GAD-7) scale\n  * On a low FODMAP diet based on FODMAP FFQ results at Screening\n  * History of following a low FODMAP diet in the past 6 months (self-reported)\n  * Any history of following LFD (Low FODMAP Diet) with no response (i.e. failed LFD in past)\n  * Participants who are on or plan to initiate a major restrictive or elimination diet, or a structured weight-loss diet, during the study period.\n  * No planned changes in diet, lifestyle or medications for IBS during study period.\n  * Use of any antibiotics, antifungals, or antivirals within 2 weeks prior to randomization.\n  * Participants planning extended travel that would interfere with compliance or study procedures.\n  * Are unlikely for any reason to be able to comply with the trial or considered unsuited for participation in the study by the Principal Investigator.",{"count":54,"type":22},150,[25],"This study is a randomized, double-blind, placebo-controlled, within-individual crossover trial designed to assess the impact of regular use of a consumer-grade FODMAP-targeting digestive enzyme blend (FODZYME®) on gastrointestinal symptoms in adults with self-reported bloating.1\n\nThe study's rationale is based on the fact that fermentable carbohydrates (FODMAPs) are often poorly absorbed and can trigger symptoms like bloating and abdominal pain. While a Low FODMAP Diet (LFD) is clinically validated for symptom relief, it is restrictive. The enzyme blend is intended to offer a more flexible, enzyme-based solution by targeting and breaking down FODMAPs, such as fructan, GOS, and lactose, before they ferment in the colon.\n\nThe primary objective is to evaluate the product's impact on bloating symptoms, measured by the mean PROMIS scale Gastrointestinal Gas and Bloating score. Secondary and exploratory objectives include assessing the impact on overall gastrointestinal symptom severity (IBS-SSS), abdominal pain (PROMIS Belly Pain score), food-related quality of life (FR-QoL-29), and anxiety (GAD-7 scores). The study also aims to evaluate these effects across various Irritable Bowel Syndrome (IBS) subgroups (IBS-C, IBS-D, IBS-M). The trial is a consumer-driven, decentralized research study utilizing validated patient-reported outcome measures that can be completed in a home setting.",[28,58,59,60],"Bloating","Abdominal Pain","Gut Health",[62,63,64,30],"bloating","gas","abdominal pain","RECRUITING","2026-05-11",{"date":68,"type":38},"2026-05-15",{"date":70,"type":38},"2026-05-04",{"date":72,"type":22},"2026-10-26",{"name":74,"class":75},"Kiwi Health Inc","INDUSTRY",{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":80,"acronym":4,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":82,"targetDuration":4,"studyType":23,"phases":84,"briefSummary":85,"conditions":86,"keywords":90,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":104},"100639939","ncws-or-ibsfd-in-relatives-of-cd-patients-100639939","NCT07584473","NCWS or IBS\u002FFD in Relatives of CD Patients","Inclusion criteria\n\n* CD patient's relatives\n* \\>18 years old\n* reporting IBS\u002FFD-like and extraintestinal (EI) symptoms\n\nExclusion criteria\n\n* self-exclusion of wheat from the diet and refuse to reintroduce it for diagnostic purposes;\n* drug and\u002For alcohol (\\>30 g\u002Fday for men and \\>20 g\u002Fday for women) abuse;\n* treatment with steroids and\u002For non-steroidal anti-inflammatory drugs in the 2 weeks before duodenal biopsy;\n* pregnancy or breastfeeding;\n* diagnosis of chronic inflammatory bowel disease or other organic pathologies affecting the digestive system \\[e.g., IgE-mediated Wheat Allergy (WA), microscopic colitis, diverticulitis, segmental colitis associated with diverticulosis, etc.\\], neurological diseases, major psychiatric disorders, infectious diseases, immunological deficiencies, and impairments limiting physical activity.",{"count":83,"type":22},600,[25],"Over 50% of non-celiac wheat sensitivity (NCWS) patients are HLA DQ2\u002FDQ8 positive and often have a Celiac Disease (CD) family history. Studies have identified a subgroup of NCWS patients whose clinical and immunological features are closer to CD than to irritable bowel syndrome\u002Ffunctional dyspepsia (IBS\u002FFD) ('inflammatory subgroup'). The investigators hypothesized that among CD patient's relatives, there might be a high number of NCWS subjects, who hypothetically belong to the 'inflammatory subgroup'. Therefore, the aim of this multi-step project is to identify the prevalence of both self-reported NCWS and IBS\u002FFD not related to wheat ingestion among CD patient's relatives (parents, grandparents, siblings and sons).",[87,28,88,89],"Non Celiac Wheat Sensitivity","Functional Dyspepsia","Celiac Disease",[91,31,92,93,94],"non celiac wheat sensitivity","functional dyspepsia","celiac disease","Relatives","2026-05-07",{"date":97,"type":38},"2026-05-13",{"date":99,"type":38},"2026-04-01",{"date":101,"type":22},"2028-04-30",{"name":103,"class":45},"University of Palermo",2,{"id":106,"slug":107,"hasResults":11,"nctId":108,"briefTitle":109,"officialTitle":110,"acronym":4,"eligibilityCriteria":111,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":112,"enrollmentInfo":113,"targetDuration":4,"studyType":23,"phases":115,"briefSummary":116,"conditions":117,"keywords":118,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":122,"lastUpdatePostDateStruct":123,"startDateStruct":125,"completionDateStruct":127,"leadSponsor":129,"locationsCount":131},"100634486","a-prospective-trial-of-a-variable-compression-system-for-moderate-to-severe-irritable-bowel-syndrome-100634486","NCT07540312","A Prospective Trial of a Variable Compression System for Moderate to Severe Irritable Bowel Syndrome","A Prospective Interventional Trial With a Non-invasive Variable Compression System (VCS) to Determine the Efficacy in Patients With Moderate to Severe Irritable Bowel Syndrome (IBS)","Inclusion Criteria:\n\n* Written informed consent to participate in the trial as prescribed.\n* Subjects with a weight of ≥50 kg and a body mass index between 18 and 40 kg\u002Fm2.\n* Diagnosed with IBS(C)-constipation, IBS(D)-diarrhea, or IBS(M)-mixed patients' diagnosis according to Rome Criteria (moderate to severe).\n\nExclusion Criteria:\n\n* Allergy to the investigational device or any components or clinically significant allergies (excluding mild seasonal allergies), in the opinion of the investigator.\n* Clinically relevant history of gastrointestinal, cardiovascular, musculoskeletal, endocrine, hematologic, psychiatric, renal, hepatic, bronchopulmonary, neurologic, immunologic, lipid metabolism disorders, or psychiatric disorders making implementation of the protocol or interpretation of the trial results difficult, or that would put the participant at risk by participating in the trial in the opinion of the Investigator.\n* Hospital admission or major surgery within 30 days prior to screening.\n* Pregnant, or positive urine pregnancy test.\n* Participation in any other investigational drug trial within 30 days prior to screening.\n* Participant with substance use disorder (SUD) and\u002For alcohol use disorder (AUD).\n* Participant who has other conditions that may affect compliance in the opinion of the investigator, or who are unable to participate in the trial on his\u002Fher own.\n* Participant with end stage organ disease.","60 Years",{"count":114,"type":22},20,[25],"This prospective, interventional trial is intended to determine the safety and effectiveness of the Variable Compression System (VCS) device for Irritable Bowel Syndrome (IBS). This pilot study will enroll 20 subjects who will be required to wear the VCS device for a minimum of 6 hours a day and follow up at 21 days, 8 weeks, and 6 months post-device administration.",[28],[119,120,121,30],"Variable Compression System","VCS","Irritable Bowel Syndrome","2026-04-23",{"date":124,"type":38},"2026-04-29",{"date":126,"type":38},"2025-05-21",{"date":128,"type":22},"2026-05-01",{"name":130,"class":75},"PGP Health",3,{"id":133,"slug":134,"hasResults":11,"nctId":135,"briefTitle":136,"officialTitle":137,"acronym":4,"eligibilityCriteria":138,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":139,"targetDuration":4,"studyType":23,"phases":141,"briefSummary":143,"conditions":144,"keywords":146,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":148,"lastUpdatePostDateStruct":149,"startDateStruct":151,"completionDateStruct":153,"leadSponsor":155,"locationsCount":46},"100571989","phase-2-efficacy-of-rifaximin-with-nac-in-ibs-d-100571989","NCT06727422","Efficacy of Rifaximin With NAC in IBS-D","A Phase 2b, Randomized, Double-Blind, Placebo- Controlled, Multicenter Study to Assess the Safety, Efficacy and Pharmacokinetics of RNIB21 in the Treatment of Patients With Irritable Bowel Syndrome With Diarrhea (IBS-D)","Inclusion Criteria:\n\n1. Male or non-pregnant, non-lactating female patients ≥ 18 years of age\n2. Diagnosed with IBS confirmed by the Rome IV criteria, with associated symptoms of diarrhea as noted below in 4(b).\n3. Do not have adequate relief of IBS symptoms of abdominal pain, stool consistency or stool frequency\n4. Have daily IBS symptom scores during screening as below:\n\n   1. Weekly average score of worst daily abdominal pain \\>3.0 on a 0-10 point scale\n   2. At least one stool with a consistency of Type 6 or 7 on the Bristol\n\nExclusion Criteria:\n\n1. Present with the following symptoms of IBS with constipation:\n\n   1. Less than 3 bowel movements a week,\n   2. Hard or lumpy stools, and\n   3. Excessive straining during a bowel movement.\n2. History of inflammatory bowel disease, celiac disease, GI surgery (except cholecystectomy and\u002For appendectomy)\n3. Evidence of active duodenal ulcer, gastric ulcer, diverticulitis, or active infectious gastroenteritis\n4. Current diagnosis of asthma\n5. Current user of NAC and\u002For rifaximin\n6. Systemic antibiotic use in the last month\n7. Not currently on a prokinetic drug\n8. A significant medical condition including but not limited to hepatic, uncontrolled diabetes, renal, cardiovascular, pulmonary, uncontrolled thyroid disease. or psychiatric disease, which in the opinion of investigator precludes study participation",{"count":140,"type":22},225,[142],"PHASE2","The purpose of this study is to examine the effectiveness of using a combination of a drug, rifaximin and a dietary supplement, N-acetyl-L-cysteine (NAC), to treat patients with irritable bowel syndrome with diarrhea (IBS-D). Rifaximin is one of the standard treatments for IBS-D and is FDA approved. While rifaximin is safe and effective for treating symptoms in patients with IBS-D, many patients find that their symptoms may not completely resolve, or may come back after a period of time.\n\nThis research study is designed to test the investigational use of a combination of rifaximin and NAC. The combination of rifaximin and NAC is not approved by the U.S. Food and Drug Administration (FDA) for the treatment of IBS-D, and the effects of taking both medications together are unknown. However, the two medications are approved for use separately, as detailed below.\n\nRifaximin is the only antibiotic approved by the FDA for the treatment of IBS-D. Rifaximin (at a dose of 550 mg by mouth three times daily for 14 days) is approved by the FDA for the treatment of IBS-D. Rifaximin (at a dose of 200 mg per mouth three times daily for 3 days) is FDA approved for the treatment of traveler's diarrhea. Rifaximin at a dose of 200 mg per mouth three times daily is not approved by the FDA for the treatment of IBS-D.\n\nNAC is approved by the FDA to treat acetaminophen overdose (72-hour oral and 21-hour intravenous (IV) regimens), and for use in breaking up mucus in the lungs in patients with chronic obstructive pulmonary disease (COPD) and other lung conditions such as bronchitis. NAC is also available over-the-counter in 600 mg and 900 mg capsules as a dietary supplement, although over-the-counter use is not regulated by the FDA. This study will utilize the 600 mg dietary supplement capsules.\n\nThe Investigators want to know if using a combination of rifaximin and NAC will give better results in decreasing IBS-D symptoms than using rifaximin alone. As NAC is used to break up mucus in the lungs, and the Investigators want to see if this can also break up the mucus layer in the small intestine, and therefore potentially increase the effectiveness of rifaximin. The Investigators will be testing 2 doses to determine which dose is most effective.\n\nparticipants are being asked to take part in this research study because participants were diagnosed with IBS-D.",[28,145],"IBS-D (Diarrhea-predominant)",[147],"IBS-D","2026-04-16",{"date":150,"type":38},"2026-04-20",{"date":152,"type":38},"2026-02-04",{"date":154,"type":22},"2027-01-01",{"name":156,"class":45},"Mark Pimentel, MD",{"id":158,"slug":159,"hasResults":11,"nctId":160,"briefTitle":161,"officialTitle":162,"acronym":163,"eligibilityCriteria":164,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":165,"enrollmentInfo":166,"targetDuration":4,"studyType":23,"phases":168,"briefSummary":169,"conditions":170,"keywords":171,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":173,"lastUpdatePostDateStruct":174,"startDateStruct":176,"completionDateStruct":178,"leadSponsor":180,"locationsCount":182},"100584472","study-evaluating-the-efficacy-of-different-mixes-of-hmo-2fl--humiome-post-lb-on-ibs-gastrointestinal-symptoms-100584472","NCT06889779","Study Evaluating the Efficacy of Different Mixes of HMO-2FL + Humiome® Post LB on IBS Gastrointestinal Symptoms","A Randomized, Placebo-controlled, Double-blind Study to Evaluate the Efficacy of Two Different Mixes of HMO-2FL + Humiome® Post LB Postbiotic (Postbiotic-LB) on Gastrointestinal Symptoms in Irritable Bowel Syndrome (IBS) Subjects","DORPHI","* Written and signed informed consent (will be obtained before any study-related Assessments).\n* Male or female aged ≥18 - 70 years at the time of consent.\n* Female individuals of childbearing potential (Females who are peri or post-menopausal, i.e., when there has been no or irregular menstruation for a minimum of 12 months prior to screening, are considered not to be of child-bearing potential.), who are not surgically sterilized, must have a negative pregnancy test at screening and be willing to practice one of the following appropriate contraceptive methods until:\n\n  * Sexual abstinence.\n  * Oral contraceptives.\n  * Trans-dermal patches or depot\n  * injection of a progestogen drug (starting at least 4 weeks prior to product administration).\n  * Double barrier method: condom or occlusive cap (diaphragm or cervical\u002Fvault caps) plus spermicidal agent.\n  * Intrauterine device (IUD), intrauterine system (IUS), subdermal implant, or vaginal ring (placed at least 4 weeks prior to product administration\u002F2 weeks prior screening).\n  * Contraceptives must be effective before the randomization visit.\n* Individuals with plasma FBG (fasting blood glucose) (less than equal to 125 mg\u002Fdl).\n* Individuals with Hemoglobin (Hb%) (more than equal to 10 g\u002Fdl).\n* Individuals with BP (blood pressure) (less than equal to 140\u002F100 mm Hg)\n* Individuals with normal haematology as assessed by CBC (complete blood counts)\n* Individuals with TSH levels in between 0.4 mIU\u002FL to 5.0 mIU\u002FL\n* Individuals with SGOT and SGPT within 2 X the Upper normal limit (ULN) and serum\n* Individuals with creatinine within 1.5 X ULN\n* Rome-IV diagnostic criteria: Individuals with more than 25% of bowel movements with Bristol stool types 1, 2 or 6,7 and have had recurrent abdominal pain, on average, at least 1 day\u002Fweek in the last 3 months. And the pain is associated with two or more of the following criteria:\n\n  * Related to defecation\n  * Associated with a change in frequency of stool\n  * Associated with a change in form or appearance of stool as\n  * assessed by Bristol stool types 1,2, 6 or 7.\n  * Individuals meeting the above criteria for the last 3 months with\n  * symptom onset at least 6 months before diagnosis\n* Individuals with Abdominal pain severity (more than equal to 6 on a 11-point scale) at screening and during placebo run-in period.\n* Individuals with IBS-SSS of at least 175 points at screening.\n* Individuals who are mentally stable as assessed by Perceived Stress Scale (PSS) less than equal to 26 (Low to Moderate stress).\n* Individuals who understand the nature and purpose of the study including the potential risks and side effects.\n* Individuals who are willing to complete all study procedures including study-related questionnaires and comply with study requirements.\n* Individuals who are capable of filling the app-based digital form\u002Fdiary.\n\nExclusion Criteria:\n\n* Individuals with IBS-M.\n* Treatment with an investigational drug within 30 days\u002F5 half-lives of the drug (whichever longest) prior to screening visit.\n* Individuals with organic disease like infectious diseases, inflammatory diseases, metabolic disorders, neurological diseases, autoimmune disorders, cancer etc. (to be ruled out by physician based on prior history and physical examination).\n* Individuals with a history of surgical resection of the stomach, small intestine or large intestine.\n* Individuals with a history of or complications from inflammatory bowel disease (Crohn's disease or ulcerative colitis), colitis and enteritis.\n* Individuals with a history of any diet-based intolerance (gluten or lactose intolerance).\n* Individuals with a history of drug or alcohol abuse within the past 6 months.\n* Individuals with severe depression or an anxiety disorder, which could potentially affect the efficacy evaluation (as determined by the qualified investigator).\n* Individuals with uncontrolled hypertension or on antihypertensive medications.\n* Individuals with serious cardiovascular diseases, respiratory diseases, renal diseases, hepatic diseases, gastrointestinal diseases (excluding IBS), blood diseases or neurological or psychiatric diseases.\n* Individuals who are pregnant, breastfeeding or planning on becoming pregnant throughout the course of the study.\n* Individuals with Type I or Type II diabetes mellitus.\n* Individuals with a history of or current diagnosis of any cancer diagnosed less than 5 years prior to screening. Individuals with cancer in full remission more than 5 years after diagnosis are acceptable.\n* Individuals who are immuno-compromised (HIV positive, on antirejection medication, rheumatoid arthritis and other autoimmune disorders).\n* Individuals with a history of abdominal surgery.\n* Individuals with diarrhoea of any other origin.\n* Individuals currently or in future planning to fast for more than 24 hours.\n* Individuals with an active eating disorder.\n* Individuals who have used an over-the-counter or prescription laxative medication or any other herbal agents affecting GI motility within 2 weeks prior to screening.\n* Individuals who have used pre\u002Fpro\u002Fpost\u002Fsynbiotic, Human Milk Oligosaccharides (HMOs), or fiber supplements (or probiotic\u002Ffiber enriched foods) or FODMAP diet or an antibiotic within 4 weeks prior to screening.\n* Individuals who have used IBS specific treatments within 4 weeks prior to screening.\n* Individuals who currently consume greater than 2 standard alcoholic drinks per day from past 3 months. ((One unit of alcohol is equal to 45 ml of hard liquor, 150 ml of wine or a pint of beer)\n* Smokers (in any number and any format)\n* Individuals with an allergy or sensitivity to the probiotic products.\n* Individuals who are cognitively impaired and\u002For who are unable to give an informed consent.\n* Individuals who have abnormal laboratory results or any other medical or psychological condition which, in the opinion of the qualified investigator, may adversely affect the Individuals' ability to complete the study or its measures or which may pose significant risk to the individual.","70 Years",{"count":167,"type":22},402,[25],"A randomized, placebo-controlled, double-blind clinical study to evaluate the efficacy of two different mixes of HMO-2'-O-fucosyllactose (HMO-2FL) + Humiome® Post LB postbiotic (postbiotic-LB) on Gastrointestinal Symptoms in individuals with Irritable Bowel Syndrome (IBS)",[28],[172],"Dietary supplement IBS","2026-03-09",{"date":175,"type":38},"2026-03-11",{"date":177,"type":38},"2025-03-27",{"date":179,"type":22},"2026-07-30",{"name":181,"class":75},"dsm-firmenich Switzerland AG",12,{"id":184,"slug":185,"hasResults":11,"nctId":186,"briefTitle":187,"officialTitle":188,"acronym":4,"eligibilityCriteria":189,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":190,"enrollmentInfo":191,"targetDuration":4,"studyType":23,"phases":193,"briefSummary":194,"conditions":195,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":200,"lastUpdatePostDateStruct":201,"startDateStruct":203,"completionDateStruct":205,"leadSponsor":207,"locationsCount":46},"100574300","lf-rtms-attenuates-visceral-pain-in-irritable-bowel-syndrome-with-diarrhea-100574300","NCT06757491","Lf-rTMS Attenuates Visceral Pain in Irritable Bowel Syndrome With Diarrhea","Low-frequency Repetitive Transcranial Magnetic Stimulation Attenuates Visceral Pain in Irritable Bowel Syndrome With Diarrhea Via Inhibition of the Medial Prefrontal Cortex","All diagnoses were made by board-certified gastroenterologists. Eligible participants met the following inclusion criteria: (1) age between 18 and 75 years; (2) fulfillment of the Rome IV diagnostic criteria for IBS-D. Exclusion criteria included: (1) presence of inflammatory or other organic gastrointestinal diseases; (2) diagnosed psychiatric disorders; (3) history of anorectal, intestinal, or abdominal surgery; (4) pregnancy or lactation; (5) presence of metallic implants or cardiac pacemakers.","75 Years",{"count":192,"type":22},42,[25],"Objectives: To identify a central hub of visceral pain in IBS-D and elucidate the mechanism by which repetitive transcranial magnetic stimulation (rTMS) confers analgesic effects.\n\nMethods: A total of 42 IBS-D patients were recruited and randomly assigned (1:1) to the sham rTMS or the rTMS group. A nested cohort of 21 IBS-D participants who completed baseline fMRI assessments prior to randomization was included. Consistent with the randomization procedure，these individuals were evenly distributed between the two groups. Both participants and outcome assessors remained blinded to treatment allocation throughout the study. All patients completed the two-week intervention and were included in the final analysis.",[196,197,198,28,199],"Repetitive Transcranial Magnetic Stimulation","Chronic Visceral Pain","Functional Magnetic Resonance Imaging","Clinical Efficacy","2025-11-18",{"date":202,"type":38},"2025-11-21",{"date":204,"type":38},"2024-08-01",{"date":206,"type":22},"2026-01-25",{"name":208,"class":45},"The First Affiliated Hospital of Soochow University",{"id":210,"slug":211,"hasResults":11,"nctId":212,"briefTitle":213,"officialTitle":214,"acronym":215,"eligibilityCriteria":216,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":217,"targetDuration":4,"studyType":23,"phases":219,"briefSummary":221,"conditions":222,"keywords":224,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":227,"lastUpdatePostDateStruct":228,"startDateStruct":229,"completionDateStruct":231,"leadSponsor":233,"locationsCount":5},"100605892","phase-3-saccharomyces-boulardii-cncm-i-745-in-irritable-bowel-syndrome-100605892","NCT07168434","Saccharomyces Boulardii CNCM I-745 in Irritable Bowel Syndrome","A Double-blind, Randomized, Placebo-controlled, Multicenter Trial Evaluating the Efficacy and Safety of Saccharomyces Boulardii CNCM I-745 in Adult Patients With Non-constipated Irritable Bowel Syndrome","BoWell Sb252","Inclusion Criteria:\n\n1. Male or female aged ≥ 18 and ≤ 65 years.\n2. Diagnosis of IBS of any subtype, except constipation predominant (IBS-C), according to Rome IV criteria.\n3. IBS-SSS total score ≥ 175 at inclusion.\n4. Able and willing to maintain their nutrition habits throughout the study participation.\n5. Able to understand and willing to comply with study requirements and to provide written informed consent.\n6. For women of childbearing potential: willing to use one or more acceptable birth control method throughout the study participation.\n\nExclusion Criteria:\n\n1. Diagnosis of IBS-C according to Rome IV criteria.\n2. Patient with more than 5 bowel movements per day on average during the screening period, according to the patient's diary (BSFS).\n3. Severe illness(es) or medical condition(s), including gastrointestinal pathologies (other than IBS): gastrointestinal ulcers, coeliac disease, inflammatory bowel disease, bowel cancer, acute or chronic diarrhea secondary to confirmed infectious gastroenteritis, or enteral or parenteral nutrition.\n4. History of abdominal surgery (except for appendectomy, cholecystectomy, surgery for hemorrhoids or cesarian section, more than 6 months prior to inclusion).\n5. Familial colorectal cancer syndrome (Lynch, Familial Adenomatous Polyposis).\n6. Fecal transplant within 6 months prior to screening.\n7. Use of products marketed as prebiotics, probiotics or synbiotics within 2 weeks prior to screening. These products, with the exception of the investigational product, will not be allowed during the trial. Regular cheese or yogurt containing lactic acid bacteria are not an exclusion criterion.\n8. Systemic antibiotic or antimycotic treatment within 2 weeks prior to randomization. These treatments are not allowed during the study.\n9. Laxatives, antibloating agents, antidiarrheal medication, antispasmodics, within 2 weeks prior to screening. These treatments are not allowed during the study, except loperamide which can be used as rescue medication.\n10. Daily or regular non-steroidal anti-inflammatory drugs (NSAIDS) at doses above cardiovascular prophylaxis (low dose aspirin) are not allowed within 2 weeks prior to screening and throughout the study participation.\n11. Use of opioids or narcotic analgesics, including tramadol and codeine, within 6 weeks prior to screening. These treatments are not allowed during the study.\n12. Treatment with two or more antidepressant\u002Fanxiolytic\u002Fantipsychotic within 3 months prior to study entry or during the trial. Treatment with a single antidepressant or anxiolytic or antipsychotic agent before and during the trial is allowed provided that the dose is stable within 3 months prior to study entry and during the trial participation.\n13. Treatment with anticholinergics for overactive bladder such as solifenacin, darifenacin, oxybutynin, tolterodine, fesoterodin, propiverin, trospium chloride, or mirabegron, within 1 week prior to screening. These treatments are not allowed during the study.\n14. Allergy to yeast, especially Saccharomyces boulardii, or known hypersensitivity to one of the components.\n15. Patients having a central venous catheter, critically ill patients, and immunocompromised patients.\n16. Patients with rare hereditary problems of galactose or fructose intolerance, total lactase deficiency, glucose-galactose malabsorption or sucrase-isomaltase insufficiency.\n17. Excessive alcohol consumption (\\>7 units\u002Fweek) and\u002For drug abuse.\n18. Other medical conditions or comorbidities, treatment, which in the opinion of the investigator, would interfere with study compliance or data interpretation.\n19. Presenting any significant biological or clinical anomalies that are not compatible with participation in the study according to the investigator.\n20. Participant at risk of pregnancy, pregnant or breastfeeding female.\n21. Participant under guardianship or curatorship.\n22. Participant under the protection of the Court or deprived of liberty.\n23. Participant participating in another interventional clinical trial which could interfere with the trial's results or impact the other trial's results; or within 5 half-lives of the study investigational treatment, whichever is longer.\n24. Participant whose current state of health does not allow him\u002Fher to give consent.",{"count":218,"type":22},406,[220],"PHASE3","This is a double-blind, randomized (group assignment by chance), placebo-controlled, multicenter trial which will be conducted over a 13.5-months period The main objective of the research is to demonstrate the efficacy of Saccharomyces boulardii CNCM I-745 on global IBS symptoms, measured by the Irritable Bowel Syndrome Symptom Severity Scale (IBS-SSS), in comparison to placebo after 8 weeks.\n\nSecondary efficacy objectives are to evaluate the impact of Saccharomyces boulardii CNCM I-745 on quality of life of IBS patients and on global and individual IBS symptoms, using the IBS-SSS, in comparison to placebo at regular intervals over a 3-month treatment period. This research also aims to evaluate the proportion of patients who improved ≥ 50 points on IBS-SSS and the proportion of responders according to the European Medicines Agency (EMA) definition (based on the patient's global assessment of efficacy and on abdominal pain score), after 8 weeks of treatment. Secondary safety objective is to evaluate the safety profile and tolerability of Saccharomyces boulardii CNCM I-745 capsules 500 mg\u002Fday in IBS patients in comparison to placebo",[28,145,223],"IBS, Mixed Symptoms",[30,121,225,226],"Saccharomyces boulardii","Non-constipated IBS","2025-11-17",{"date":200,"type":38},{"date":230,"type":38},"2025-10-22",{"date":232,"type":22},"2026-10-11",{"name":234,"class":75},"Biocodex",{"id":236,"slug":237,"hasResults":11,"nctId":238,"briefTitle":239,"officialTitle":240,"acronym":241,"eligibilityCriteria":242,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":243,"targetDuration":4,"studyType":23,"phases":245,"briefSummary":247,"conditions":248,"keywords":250,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":252,"lastUpdatePostDateStruct":253,"startDateStruct":255,"completionDateStruct":257,"leadSponsor":259,"locationsCount":104},"100611300","early-phase-1-use-of-a-complex-gut-bacterial-consortium-miti-001-for-the-treatment-of-irritable-bowel-syndrome-with-diarrhea-100611300","NCT07238790","Use of A Complex Gut Bacterial Consortium (MITI 001) for the Treatment of Irritable Bowel Syndrome With Diarrhea","A Phase 1 Study to Evaluate the Safety of a Complex Gut Bacterial Consortium (MITI 001) for the Treatment of Irritable Bowel Syndrome With Diarrhea","CURE-IBS-D","Inclusion Criteria:\n\n1. Age 18 to 65 years inclusive at the time of signing the informed consent.\n2. Diagnosis of IBS-D according to the Rome IV criteria (Lacy 2017).\n3. At least 1 of the following measures of microbiome dysfunction:\n\n   1. Primary bile acid proportion ≥ 12% in stool samples, or\n   2. Positive hydrogen breath test (with either glucose or lactulose substrate) (Rezaie 2017)\n4. Normal C-reactive protein level\n5. Gallbladder intact\n6. Willing to use appropriate contraception during the treatment period and for one week after the last study visit.\n\n   * Male participants with partners who are women of childbearing potential (WOCBP): Appropriate contraception includes condoms or other means considered adequate by the responsible Investigator.\n   * Female participants who are WOCBP: Appropriate contraception includes condoms, an intrauterine device, hormonal contraception, or other means considered adequate by the responsible Investigator.\n7. Capable of giving signed informed consent as described in Appendix 1, which includes compliance with the requirements and restrictions listed in the informed consent form and in this protocol.\n8. Able to tolerate the planned course of antibiotics, EGD, and colonoscopy with bowel lavage.\n\nExclusion Criteria:\n\n1. Inflammatory bowel disease\n2. Untreated enteric infections\n3. History of gastrointestinal (GI) surgery: All participants with GI surgeries below the pylorus will be excluded from this study. This includes participants with a history of colectomy, segmental colonic resection, and small bowel resections.\n4. Documented severe gastroparesis\n5. Active intestinal obstruction\n6. Dysphagia (oropharyngeal, esophageal, functional, or neuromuscular)\n7. History of recurrent aspiration episodes\n8. Any conditions associated with a high risk of bleeding, including but not limited to coagulopathy\u002Fbleeding disorder, severe liver disease, active or recent GI bleeding, or recent abdominal or other GI surgery\n9. Active diagnosis of major depressive disorder\n10. Severe immunodeficiency, inherited or acquired (e.g., human immunodeficiency virus, active chemotherapy or immunosuppressive medications \\[including steroids, biologic therapy, or bone marrow suppressive agent\\], or radiation therapy)\n11. Any other significant medical condition that could confound or interfere with evaluation of safety or tolerability or prevent compliance with the study protocol at the discretion of the Investigator\n12. Active antibiotic use (except protocol-specified antibiotics)\n13. Active treatment with high levels of immunosuppressive therapies (active chemotherapy or immunosuppressive medications \\[including steroids, biologic therapies, or bone marrow suppressive agents\\], or radiation therapy)\n14. Active anticoagulant or antiplatelet therapy, or use of other medications associated with a high risk of bleeding within 48 hours prior to endoscopy on Day 1\n15. Use of a probiotic within one month prior to dosing of MITI-001 on Day 1\n16. Simultaneous participation in another interventional clinical trial\n17. Renal insufficiency (estimated glomerular filtration rate \\\u003C 50 mL\u002Fmin)\n18. Absolute neutrophil count \\\u003C 1000 μL, platelet count \\\u003C 50 × 109\u002FL, or hemoglobin level \\\u003C 6.5 g\u002FdL\n19. Pregnant, breastfeeding, or planning pregnancy during the study period\n20. Active drug or alcohol use disorder\n21. Known allergy or anaphylaxis to vancomycin, metronidazole, ciprofloxacin, or polyethylene glycol\n22. Inability to comply with research requirements",{"count":244,"type":22},13,[246],"EARLY_PHASE1","While the pathophysiology of diarrhea-predominant irritable bowel syndrome (IBS-D) is complex and heterogeneous, dysbiosis of the gut microbiome is frequently observed, suggesting that a substantial subset of patients with irritable bowel syndrome (IBS) have symptoms that are initiated and\u002For perpetuated by a microbiome dysfunction. Successful randomized controlled trials (RCT) for IBS-D (Ford 2018; Black 2022) leveraging microbiome-targeted therapies (antibiotics or low microbiome fermentation diets) suggest the gut microbiome is at least partially involved in IBS symptoms. Furthermore, fecal microbiota transplantation (FMT) for patients with IBS-D has demonstrated promising results (El-Salhy 2020), supporting the possibility that altering the microbiome composition could ameliorate IBS-D symptoms.\n\nMITI-001 is a transplantable gut bacterial community composed of 157 live bacterial strains, encompassing 79 genera of commensal bacteria, that have been isolated from healthy donor stool, purified, and banked. The hypothesis of the proposed research is that MITI-001 can target the pathophysiologic lesion in a subset of IBS-D patients, restore the altered microbial metabolic process, and thus alleviate IBS-D symptoms.",[28,249],"Diarrhea",[251],"IBS with Diarrhea Predominance (IBS-D)","2025-11-16",{"date":254,"type":38},"2025-11-20",{"date":256,"type":22},"2025-12",{"date":258,"type":22},"2030-12",{"name":260,"class":45},"Stanford University",{"id":262,"slug":263,"hasResults":11,"nctId":264,"briefTitle":265,"officialTitle":266,"acronym":267,"eligibilityCriteria":268,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":190,"enrollmentInfo":269,"targetDuration":4,"studyType":23,"phases":271,"briefSummary":272,"conditions":273,"keywords":274,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":280,"lastUpdatePostDateStruct":281,"startDateStruct":283,"completionDateStruct":285,"leadSponsor":287,"locationsCount":4},"100606175","transcranial-magnetic-stimulation-and-pharmacologicprobiotic-interventions-for-diarrhea-predominant-ibs-100606175","NCT07172139","Transcranial Magnetic Stimulation and Pharmacologic\u002FProbiotic Interventions for Diarrhea-Predominant IBS","Effect of Transcranial Magnetic Stimulation vs Sham Stimulation Combined With Pinaverium Bromide vs Bifidobacteria in Diarrhea-Predominant Irritable Bowel Syndrome: A 2×2 Factorial Randomized Clinical Trial","rTMS","Inclusion Criteria:\n\n(I)Age range 18-75 years (either sex) (II)Fulfilling the Rome IV criteria for irritable bowel syndrome diagnosis (III)Bristol stool type 6-7 in \\>25% and type 1-2 in \\\u003C25% of bowel movements (IV)Patients experienced Bristol stool type 6 or 7 on ≥4 days with mean abdominal pain score ≥3 during the initial 2-week period\n\nExclusion Criteria:\n\n(I)Documented organic gastrointestinal pathology; endocrinologic or metabolic diseases with known gastrointestinal motility effects including diabetes mellitus and hyperthyroidism; previous surgical interventions involving abdominal cavity intestinal tract or anal region (II)current use of any medication with documented effects on gastrointestinal motility or secretory function; administration of concurrent therapies or pharmacologic agents capable of confounding treatment efficacy or safety evaluations (III)pregnancy lactation or postpartum status within 12 months (IV)noncompliance with randomized treatment allocation or demonstrated poor adherence tendencies",{"count":270,"type":22},140,[25],"What is the study about? This study is for adults with diarrhea-predominant irritable bowel syndrome (IBS-D) who suffer from chronic visceral pain. We aim to investigate whether combining two different treatment approaches is more effective in alleviating IBS-D symptoms than either treatment alone. The first treatment is a non-invasive brain stimulation technique called repetitive Transcranial Magnetic Stimulation (rTMS), while the second treatment involves either an intestinal antispasmodic medication (Pinaverium Bromide) or a probiotic (Bifidobacterium).\n\nWhat will participants do?\n\nParticipants will be randomly assigned by a computer to one of four groups:\n\n1. Group 1: Receive real rTMS sessions + take Pinaverium Bromide pills.\n2. Group 2: Receive real rTMS sessions + take Bifidobacterium pills.\n3. Group 3: Receive fake (sham) rTMS sessions + take Pinaverium Bromide pills.\n4. Group 4: Receive fake (sham) rTMS sessions + take Bifidobacterium pills.\n\nNeither the participant nor the doctor giving the treatments will know which group the participant is in for the rTMS part (this is called \"blinding\"). The study will involve several weeks of treatment and follow-up visits to track symptoms.\n\nWhat are the potential benefits and risks? Potential Benefits: Participants may experience a reduction in their abdominal pain, diarrhea, and other IBS symptoms. However, benefit cannot be guaranteed. The information from this study may help other IBS patients in the future.\n\nPotential Risks: rTMS is generally safe but may cause mild headache, scalp discomfort, or lightheadedness. The medications may have side effects like any drug, which will be explained in detail before the study starts.\n\nWhy is this study important? This is the first study to test how brain stimulation and gut-focused treatments work together for IBS pain. The results could lead to new and more effective combination therapies for people who don't get enough relief from current treatments.",[28],[275,276,277,278,279],"Diarrhea-predominant Irritable Bowel Syndrome","repetitive Transcranial Magnetic Stimulation","Pinaverium Bromide","Bifidobacterium","chronic visceral pain","2025-09-07",{"date":282,"type":38},"2025-09-15",{"date":284,"type":22},"2025-09",{"date":286,"type":22},"2026-05",{"name":288,"class":45},"Rui Li"]